Journal of Clinical Psychopharmacology最新文献_第10页

A Case of Tachyphylaxis After Long-Term Intravenous Racemic Ketamine for Treatment-Resistant Depression. 一例因长期静脉注射消旋氯胺酮治疗难治性抑郁症而出现的过速反应

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-04-10 DOI: 10.1097/JCP.0000000000001839

Stefanie Cavalcanti, Olga A Lopez, Simon Kung, J. V. Vande Voort, Kristin J. Somers, Mark A. Frye, Balwinder Singh

引用次数: 0

Managing a Treatment-Resistant Schizophrenia Spectrum Disorder With a Hormonal Twist in a Female Patient: A Case Report of a Progestin-Only Pill. 用激素治疗女性患者的耐药性精神分裂症谱系障碍：仅使用孕激素避孕药的病例报告。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-04-09 DOI: 10.1097/JCP.0000000000001836

Mauro Scala, Paula Martínez Trapote, Roberto Rodriguez-Jimenez, B. Pecorino, Alessandro Serretti

引用次数: 0

Fifty-Nine-Year-Old Woman With Concurrent Administration of Cobicistat and Dexamethasone Potentially Leading to Mania: A Case Report. 59岁女性同时服用考比司他和地塞米松可能导致躁狂症：病例报告。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-04-08 DOI: 10.1097/JCP.0000000000001842

Gerald Cheng, Sunpreet Singh, Christopher Garabet, Mark Ard

引用次数: 0

Can slow personalized titration using C-Reactive Protein monitoring decrease the high rates and mortality of clozapine-associated myocarditis seen in some countries? A call for research. 使用 C 反应蛋白监测进行缓慢的个性化滴定能否降低某些国家氯氮平相关心肌炎的高发病率和死亡率？研究呼吁。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-03-29 DOI: 10.1097/jcp.0000000000001843

Jose de Leon

引用次数: 0

Serotonin Syndrome With the Concomitant Use of Triptans and SSRIs/Serotonergic Medications: Is It Time to Revisit FDA Warning? 同时使用 Triptans 和 SSRIs/羟色胺能药物的羟色胺综合征：是时候重新审视 FDA 的警告了吗？

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-03-01 Epub Date: 2024-01-15 DOI: 10.1097/JCP.0000000000001812

Zeeshan Mansuri, Mahwish Adnan, Bhumika Shah, Chintan Trivedi, Ramu Vadukapuram, Shweta Patel, Garima Yadav, Sushma Srinivas, Maliha Ansari, Ramkrishna Makani, Raman Baweja, Abhishek Reddy

引用次数: 0

Effect of Cigarette Smoking on Clozapine Dose and on Plasma Clozapine and N-Desmethylclozapine (Norclozapine) Concentrations in Clinical Practice: Erratum. 临床实践中吸烟对氯氮平剂量及血浆中氯氮平和 N-去甲氯氮平（诺氯氮平）浓度的影响：勘误。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-03-01 DOI: 10.1097/JCP.0000000000001829

引用次数: 0

Early Onset of Tardive Dyskinesia in an Antipsychotic-Naive Patient Treated With Low-Dose Cariprazine. 使用小剂量开浦嗪治疗的抗精神病药物无效患者早期出现迟发性运动障碍

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-03-01 DOI: 10.1097/JCP.0000000000001809

Konstantinos Tsamakis, Maria Pantazidi, Evangelos Alevyzakis, Dimitrios Tsiptsios, Christoph Mueller, Nikolaos Smyrnis, Emmanouil N Rizos

引用次数: 0

Semaglutide Misuse in Atypical Anorexia Nervosa-A Case Report. 非典型神经性厌食症患者误用塞马鲁肽--病例报告。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-03-01 Epub Date: 2024-02-07 DOI: 10.1097/JCP.0000000000001820

Anna I Guerdjikova, Anna Ward, Mack Ontiveros, Susan L McElroy

引用次数: 0

Pharmacoepidemiology and Clinical Correlates of Lithium Treatment for Bipolar Disorder in Asia. 亚洲双相情感障碍锂治疗的药物流行病学与临床相关性》（Pharmacoepidemiology and Clinical Correlates of Lithium Treatment for Bipolar Disorder in Asia）。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-03-01 Epub Date: 2024-01-16 DOI: 10.1097/JCP.0000000000001813

Yao Kang Shuy, Sanjana Santharan, Qian Hui Chew, Shih-Ku Lin, Wen-Chen Ouyang, Chih-Ken Chen, Seon-Cheol Park, Ok-Jin Jang, Jun Hyuk Park, Kok-Yoon Chee, Kwong Sen Ding, Jamaline Chong, Ling Zhang, Keqing Li, Xiaomin Zhu, Chonnakarn Jatchavala, Pornjira Pariwatcharakul, Roy A Kallivayalil, Sandeep Grover, Ajit Avasthi, Moin Ansari, Margarita M Maramis, Paing Phyo Aung, Chay Hoon Tan, Yu-Tao Xiang, Mian-Yoon Chong, Yong Chon Park, Takahiro A Kato, Naotaka Shinfuku, Ross J Baldessarini, Kang Sim

{"title":"Pharmacoepidemiology and Clinical Correlates of Lithium Treatment for Bipolar Disorder in Asia.","authors":"Yao Kang Shuy, Sanjana Santharan, Qian Hui Chew, Shih-Ku Lin, Wen-Chen Ouyang, Chih-Ken Chen, Seon-Cheol Park, Ok-Jin Jang, Jun Hyuk Park, Kok-Yoon Chee, Kwong Sen Ding, Jamaline Chong, Ling Zhang, Keqing Li, Xiaomin Zhu, Chonnakarn Jatchavala, Pornjira Pariwatcharakul, Roy A Kallivayalil, Sandeep Grover, Ajit Avasthi, Moin Ansari, Margarita M Maramis, Paing Phyo Aung, Chay Hoon Tan, Yu-Tao Xiang, Mian-Yoon Chong, Yong Chon Park, Takahiro A Kato, Naotaka Shinfuku, Ross J Baldessarini, Kang Sim","doi":"10.1097/JCP.0000000000001813","DOIUrl":"10.1097/JCP.0000000000001813","url":null,"abstract":"Background: As clinical practices with lithium salts for patients diagnosed with bipolar disorder (BD) are poorly documented in Asia, we studied the prevalence and clinical correlates of lithium use there to support international comparisons.Methods: We conducted a cross-sectional study of use and dosing of lithium salts for BD patients across 13 Asian sites and evaluated bivariate relationships of lithium treatment with clinical correlates followed by multivariate logistic regression modeling.Results: In a total of 2139 BD participants (52.3% women) of mean age 42.4 years, lithium salts were prescribed in 27.3% of cases overall, varying among regions from 3.20% to 59.5%. Associated with lithium treatment were male sex, presence of euthymia or mild depression, and a history of seasonal mood change. Other mood stabilizers usually were given with lithium, often at relatively high doses. Lithium use was associated with newly emerging and dose-dependent risk of tremors as well as risk of hypothyroidism. We found no significant differences in rates of clinical remission or of suicidal behavior if treatment included lithium or not.Conclusions: Study findings clarify current prevalence, dosing, and clinical correlates of lithium treatment for BD in Asia. This information should support clinical decision-making regarding treatment of BD patients and international comparisons of therapeutic practices.","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"117-123"},"PeriodicalIF":2.9,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139477375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy of Long-Acting Injectable Antipsychotics Versus Oral Antipsychotics in Preventing Psychiatric Rehospitalizations. 长效注射抗精神病药与口服抗精神病药在预防精神病患者再次入院方面的功效。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-03-01 Epub Date: 2024-01-16 DOI: 10.1097/JCP.0000000000001810

Pragya Thaman, Caitlin E Kulig, Daniel Greer

{"title":"Efficacy of Long-Acting Injectable Antipsychotics Versus Oral Antipsychotics in Preventing Psychiatric Rehospitalizations.","authors":"Pragya Thaman, Caitlin E Kulig, Daniel Greer","doi":"10.1097/JCP.0000000000001810","DOIUrl":"10.1097/JCP.0000000000001810","url":null,"abstract":"Purpose/background: Schizophrenia is a chronic, debilitating mental illness that incurs a large economic burden. Decreasing hospital readmissions is a priority in health care to improve patient quality of life and decrease health care costs. Determining ways to prevent readmissions such as improving access to long-acting injectable (LAI) antipsychotics is important to assess.Methods/procedures: A single-center retrospective review was conducted comparing readmission rates of patients diagnosed with schizophrenia or schizoaffective disorder discharged on LAI or oral antipsychotics between August 1, 2019, and June 30, 2022. The primary outcome was the 30-day psychiatric readmission rate. Secondary outcomes included chlorpromazine equivalent doses and use of anticholinergic medications.Findings/results: The 30-day readmission rate was 1.9% for the LAI antipsychotic group and 8.3% for the oral antipsychotic group ( P = 0.03; 95% confidence interval, 1.05-20.02). The average chlorpromazine equivalent antipsychotic dose of patients discharged on LAI versus oral antipsychotic medications was 477.3 and 278.6 mg/d, respectively ( P < 0.001). In addition, the prevalence of medications used to treat extrapyramidal symptom was 22.3% (n = 23) for the LAI antipsychotic group and 30.8% (n = 74) for the oral antipsychotic group ( P = 0.12). Sixty-four percent of LAI antipsychotics utilized were obtained from pharmaceutical company hospital inpatient free trial programs.Implications/conclusions: Long-acting injectable antipsychotics showed a statistically significant reduction in 30-day rehospitalizations as compared with oral antipsychotics and hospital inpatient free trial programs aided in LAI antipsychotic acquisition.","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"96-99"},"PeriodicalIF":2.9,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139477453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0